Stuart Cobb - 13 Mar 2026 Form 4 Insider Report for Neurogene Inc. (NGNE)

Reporting relationship: Chief Scientific Officer
Issuer ticker: NGNE
Reported as of: 13 Mar 2026
Net transaction value: -$141,446
SEC form: 4
Accepted by SEC: 17 Mar 2026, 18:01:47 UTC
Prior SEC filing: 24 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Donna M Cochener, as attorney-in-fact for Stuart Cobb

Key filing fact

Stuart Cobb filed Form 4 for Neurogene Inc. (NGNE) on 17 Mar 2026.

Key facts

This page summarizes Stuart Cobb's Form 4 filing for Neurogene Inc. (NGNE).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 17 Mar 2026, 18:01.

Change

Previous filing in this sequence was filed on 24 Feb 2026.
Current net transaction value: -$141,446.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001994301 Primary reporting owner

Cobb Stuart

Relationship: Chief Scientific Officer
Address: C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR, NEW YORK
Signature: /s/ Donna M Cochener, as attorney-in-fact for Stuart Cobb
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NGNE transaction

Common Stock

Sale

Transaction value: $81,456
Shares: -3,991
Change %: -11%
Price: $20.41
Shares after: 33,303
Date: 13 Mar 2026
Ownership: Direct
Footnotes: F1, F2, F3

NGNE transaction

Common Stock

Sale

Transaction value: $56,722
Shares: -2,658
Change %: -8%
Price: $21.34
Shares after: 30,645
Date: 13 Mar 2026
Ownership: Direct
Footnotes: F1, F3, F4

NGNE transaction

Common Stock

Sale

Transaction value: $3,268
Shares: -148
Change %: -0.48%
Price: $22.08
Shares after: 30,497
Date: 13 Mar 2026
Ownership: Direct
Footnotes: F1, F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.94 to $20.93, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

Footnote F4

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.97 to $21.96, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.97 to $22.16, inclsuive. The reporting person undertakes to provide Neurogene Inc. the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.